Study Shows No Relapse After Pregnancy for Women With Multiple Sclerosis

This article was originally published by MD Magazine.

Two decades ago, before the availability of disease-modifying therapies, pregnant women with multiple sclerosis (MS) were found to face significantly higher risks of relapse in the months following pregnancy.

Since then, the world of MS care has changed vastly, with new therapies and better technology to quickly diagnose MS. Those advances led a team of investigators from Kaiser Permanente to pose the question of whether the conventional wisdom about MS and pregnancy should change, too.

The investigators looked at 466 pregnancies among 375 women with MS who received care at Kaiser Permanente’s Southern California and Northern California facilities between the years 2008 - 2016. Only patients who had complete electronic health records were included in the study. EHR data were coupled with survey responses from interviews with patients.

The news was good: the data showed no rebound effect after pregnancy for women with MS.

“This shows us that women with MS today can have children, breastfeed, and resume their treatment without experiencing an increased risk of relapses during the postpartum period,” first author Annette Langer-Gould, MD, PhD, of Kaiser Permanente Southern California, said in a statement.

Langer-Gould did not respond to a request for comment at the time of publication.

The findings were released this month ahead of the American Academy of Neurology (AAN) 71st Annual Meeting in Philadelphia, PA, in May, and the study will be presented at the conference.

Nearly 1 in 4 women in the study (38%) were not on any treatment in the year prior to their pregnancy. Meanwhile, 14.6% of patients had clinically isolated syndrome, the first neurological episode for patients developing MS. Eight percent of women in the study relapsed during pregnancy.

When investigators calculated annualized relapse rates (ARRs), they found a rate of 0.39 for the year prior to pregnancy, a 0.14 ARR during pregnancy, and a 0.27 rate in the first 3 months post-pregnancy. Between the fourth and sixth months post-pregnancy, the ARR returned to pre-pregnancy levels.

The investigators found patients who exclusively breastfed their babies had lower rates of relapse. Specifically, women who breastfed exclusively for at least 2 months had a 40% lower rate of relapse compared to women who did not breastfeed. Resuming modestly effective disease-modifying therapies (DMTs) did not have a statistically significant impact on relapse rates.

In the study, 87% of enrollees breastfed during the first postpartum year, and 35% breastfed exclusively. Forty-one percent of patients resumed DMTs during the first year after pregnancy.

As for the apparent lower risk of relapse after pregnancy, the investigators suggested in could have to do with the study population, which included women who were diagnosed after only one relapse, and a higher proportion of women who breastfed exclusively compared to the general public.

Langer-Gould also noted that the study included only a small number of patients who had been treated with natalizumab or fingolimod. She told AAN that patients on those medications tend to have more severe symptoms. The small number of patients on those drugs meant investigators was unable to quantify what risks, if any, are faced by women who stop those drugs in order to get pregnant.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Research highlights the importance of regular blood testing to impove earlier detection of multiple myeloma.
Aspirin therapy found to improve liver function test results and survival after transarterial embolization for hepatocellular carcinoma.
Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.